Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity

被引:119
作者
Ke, Hengming [1 ]
Wang, Huanchen
机构
[1] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
D O I
10.2174/156802607779941242
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Crystal structures of seven phosphodiesterase families (PDE1-5, 7, 9) show a conserved core catalytic domain that contains about 300 amino acids and fourteen (x-helices. The catalytic domains of the PDE families 1-4, 7, and 9 have a uniform conformation. However, the H-loop at the active site of PDE5 shows four different conformations upon binding of inhibitors, probably implying a special mechanism for recognition of substrates and inhibitors by PDE5. The active site of all PDE families contains two divalent metal ions: zinc and probably magnesium. The PDE4-AMP and PDE5-GMP structures reveal the conserved interactions of the phosphate groups of the products AMP and GMP, and thus suggest a universal mechanism of nucleophilic attack for all PDE families. The substrate specificity has not been well understood. This review will comment on the early proposal, "glutamine switch", on basis of the recent biochemical and structural information. The PDE-inhibitor structures have identified a common subpocket for non-selective binding of all inhibitors and potential elements for recognition of family-selective inhibitors. The kinetic analysis on the mutations of PDE7 to PDE4 suggests that the multiple elements must work together to define inhibitor selectivity.
引用
收藏
页码:391 / 403
页数:13
相关论文
共 50 条
[1]  
ALELRTON CM, 2006, J MED CHEM, V49, P3581
[2]  
Barnette M S, 2000, Curr Opin Pulm Med, V6, P164, DOI 10.1097/00063198-200003000-00014
[3]  
Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949
[4]   A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].
Card, GL ;
Blasdel, L ;
England, BP ;
Zhang, C ;
Suzuki, Y ;
Gillette, S ;
Fong, D ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207
[5]   Structural basis for the activity of drugs that inhibit phosphodiesterases [J].
Card, GL ;
England, BP ;
Suzuki, Y ;
Fong, D ;
Powell, B ;
Lee, B ;
Luu, C ;
Tabrizizad, M ;
Gillette, S ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
STRUCTURE, 2004, 12 (12) :2233-2247
[6]   Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors [J].
Castro, A ;
Jerez, MJ ;
Gil, C ;
Martinez, A .
MEDICINAL RESEARCH REVIEWS, 2005, 25 (02) :229-244
[7]  
Corbin JD, 2002, INT J CLIN PRACT, V56, P453
[8]   Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5) [J].
Fink, TL ;
Francis, SH ;
Beasley, A ;
Grimes, KA ;
Corbin, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (49) :34613-34620
[9]   Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase [J].
Fisher, DA ;
Smith, JF ;
Pillar, JS ;
St Denis, SH ;
Cheng, JB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) :15559-15564
[10]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157